Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tamiflu Population Differences Could Be Studied In U.K, HMO Databases

Executive Summary

Population differences with regard to serious adverse events in patients receiving Roche's antiviral Tamiflu could be explored using large databases, such as the U.K. General Practitioner Research Database and the UnitedHealthcare database, FDA's Pediatric Advisory Committee suggested on Nov. 18

You may also be interested in...



Tamiflu Data Reassures FDA Panel; Label Changes To Stress Flu’s Role In AEs

Despite the fact that safety questions linked to Roche's influenza drug Tamiflu (oseltamivir) are still lingering, the data on the drug presented by the firm to FDA's Pediatric Advisory Committee is proof that the "system worked," panelists said at the Nov. 27 meeting

Tamiflu Data Reassures FDA Panel; Label Changes To Stress Flu’s Role In AEs

Despite the fact that safety questions linked to Roche's influenza drug Tamiflu (oseltamivir) are still lingering, the data on the drug presented by the firm to FDA's Pediatric Advisory Committee is proof that the "system worked," panelists said at the Nov. 27 meeting

Avian Flu Plan From Administration Places Vaccines First, Antivirals Second

The Bush Administration's pandemic flu preparedness plans call for a dramatic expansion in the stockpiling of antivirals, an increase expected to be largely paid for by the states

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel